NIKKEI 225
37,628.48 -831.60 (-2.16%) HANG SENG
17,276.74 +75.47 (+0.44%) CRUDE OIL
82.89 +0.08 (+0.10%) GOLD FUTURES
2,331.60 -6.80 (-0.29%) DOW
38,460.92 -42.77 (-0.11%) Bitcoin GBP
51,397.32 -2,025.94 (-3.79%)
Ultimovacs ASA (ULTIO.OL)
- Globe Newswire
Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
NON-REGULATORY PRESS RELEASE Oslo, April 24, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announces that the data from the Phase II clinical trial INITIUM (NCT04382664), will be presented in a poster session at the 2024 ASCO Annual Meeting, taking place May 31 – June 4, 2024, in Chicago, IL & Online. INITIUM is an Ultimovacs-sponsored randomized, comparative, multicenter Phase II trial evaluating the co
- GlobeNewswire
Ultimovacs ASA – Annual General Meeting held on April 18, 2024
Oslo, April 18, 2023: Ultimovacs ASA held its annual general meeting today April 18, 2024. All the matters on the agenda were approved. The following board members were re-elected for a period of one year, and the Board of Directors will consist of the following persons: Jónas Einarsson, Chair of the BoardHenrik Schüssler, board member Kari Grønås, board member Ketil Fjerdingen, deputy board member The Nomination Committee will consist of the following persons until the Annual General Meeting in
- GlobeNewswire
Ultimovacs Implements Operational Adjustments to Support Continuous Advancement of the UV1 Vaccine Phase II Program
Due to the broad diversity in the UV1 Phase II program and the encouraging results from previous UV1 trials, Ultimovacs remain confident in UV1’s potential and are strongly committed to bringing the company across the next important data points: The readout from FOCUS in Q3 2024 and DOVACC results in H1 2025Activity level adjustments and operational prioritization are implemented to sustain the financial runway, including a workforce reduction of approximately 40% The operational adjustment plan
